QIFENG
873169
LEETRO
430425
KSEC Intelligent Technology
301311
4
Guangdong Topstar Technology
300607
5
Hengerda New Materials
300946
CN Stock MarketDetailed Quotes
688363 Bloomage Biotechnology Corporation Limited
- 48.75
- -0.25-0.51%
Market Closed May 12 15:00 CST
23.48BMarket Cap716.91P/E (TTM)
49.00High48.42Low23.28KlotVolume49.00Open49.00Pre Close113.30MTurnover0.48%Turnover Ratio134.67P/E (Static)481.68MShares84.5952wk High3.39P/B23.48BFloat Cap42.5152wk Low58.80Limit Up481.68MShs Float313.10Historical High39.20Limit Down1.18%Amplitude42.51Historical Low0.38Dividend TTM48.66Avg Price13.96KlotAsk0.78%Div YieldTTM100Lot Size8.00KlotBid
Bloomage Biotechnology Corporation Limited Key Stats
All
YOY
| (Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -20.77%1.08B | -11.61%5.37B | -8.21%3.87B | -8.61%2.81B | 4.24%1.36B | -4.45%6.08B | -2.29%4.22B | 4.77%3.08B | 4.01%1.31B | 28.53%6.36B |
| Operating revenue | -20.77%1.08B | -11.61%5.37B | -8.21%3.87B | -8.61%2.81B | 4.24%1.36B | -4.45%6.08B | -2.29%4.22B | 4.77%3.08B | 4.01%1.31B | 28.53%6.36B |
| Total operating cost | -9.44%944.32M | -7.33%5.04B | -7.48%3.42B | -9.82%2.37B | -6.91%1.04B | 2.18%5.44B | 3.50%3.7B | 8.97%2.63B | 9.47%1.12B | 27.75%5.32B |
| Operating cost | -9.09%300.18M | -14.09%1.39B | -11.13%1.01B | -11.12%716.28M | -3.51%330.18M | 10.78%1.62B | 15.54%1.14B | 21.65%805.88M | 19.25%342.19M | 34.83%1.46B |
| Operating tax surcharges | -2.92%14.6M | -2.35%65.52M | 9.64%49.07M | 15.15%34.52M | 60.11%15.04M | -13.08%67.1M | -11.92%44.76M | -19.52%29.98M | -29.25%9.4M | 33.84%77.2M |
| Operating expense | -19.63%394.12M | -13.31%2.46B | -16.04%1.63B | -17.02%1.18B | -19.02%490.36M | -6.79%2.84B | -4.29%1.94B | 2.40%1.42B | 6.94%605.51M | 25.17%3.05B |
| Administration expense | 16.30%135.02M | 33.77%658.39M | 32.30%422.95M | 19.94%246.47M | 35.07%116.09M | 25.27%492.17M | 17.22%319.68M | 17.53%205.48M | 9.52%85.95M | 29.67%392.87M |
| Financial expense | 2.18%-4.57M | 77.41%-6.96M | 71.45%-7.14M | 63.21%-8.22M | 22.76%-4.68M | 36.71%-30.79M | 42.39%-24.99M | 28.60%-22.33M | -94.71%-6.05M | -9,735.84%-48.66M |
| -Interest expense (Financial expense) | 46.78%1.89M | -64.75%2.2M | -67.85%1.65M | -62.85%1.4M | -19.79%1.29M | -31.89%6.23M | -18.52%5.13M | -7.04%3.76M | -19.70%1.61M | 40.84%9.15M |
| -Interest Income (Financial expense) | 73.14%-1.61M | 63.31%-14.11M | 58.64%-12.24M | 52.98%-10.04M | 45.72%-5.99M | 0.19%-38.46M | -6.57%-29.6M | -11.59%-21.35M | -13.64%-11.03M | -57.75%-38.53M |
| Research and development | 9.64%104.97M | 4.46%466.25M | 12.99%313.1M | 7.40%200.52M | 15.14%95.74M | 14.98%446.35M | -0.06%277.11M | 4.04%186.7M | 2.05%83.15M | 36.52%388.19M |
| Credit Impairment Loss | 5.58%-21.67M | -488.72%-29.81M | -250.78%-39.83M | -214.75%-31.97M | -449.23%-22.95M | 72.94%-5.06M | -37.81%-11.36M | -34.48%-10.16M | 34.63%-4.18M | -145.88%-18.71M |
| Asset Impairment Loss | 113.79%983.64K | -192.42%-159.09M | -376.09%-18.15M | -10,251.65%-21.81M | -641.82%-7.14M | -252.19%-54.4M | 75.95%-3.81M | 98.66%-210.69K | 133.64%1.32M | 48.21%-15.45M |
| Other net revenue | ||||||||||
| Fair value change income | ---3.41K | -3.56%1.42M | -86.39%32.14K | -86.48%35.26K | ---- | 1,129.38%1.47M | -94.91%236.07K | -91.13%260.75K | -111.11%-185.86K | -101.93%-142.58K |
| Invest income | -126.89%-3.61M | -1,044.45%-12.54M | -369.49%-5M | -292.15%-3.07M | -185.52%-1.59M | -88.86%1.33M | -76.09%1.85M | -64.25%1.6M | 26.06%1.86M | -42.29%11.92M |
| -Including: Investment income associates | -134.48%-4.71M | -738.57%-13.85M | -322.19%-6.14M | -211.02%-4.03M | -240.37%-2.01M | 30.03%-1.65M | -82.41%-1.45M | -209.99%-1.3M | -165.90%-589.57K | -586.25%-2.36M |
| Asset deal income | ---- | 96.53%-118.9K | ---7.94K | ---- | ---- | -600.72%-3.42M | ---- | ---- | ---- | -1,240.60%-488.68K |
| Other revenue | 72.67%24.52M | -34.88%85.17M | -55.86%43.5M | -60.17%30.45M | -76.04%14.2M | 7.04%130.79M | 16.29%98.55M | 8.71%76.44M | 238.33%59.29M | -8.18%122.19M |
| Operating profit | -55.44%133.83M | -69.52%215.94M | -28.64%436.12M | -19.58%416.28M | 23.53%300.32M | -37.66%708.39M | -25.70%611.16M | -10.76%517.61M | 0.49%243.12M | 25.48%1.14B |
| Add:Non operating Income | -47.70%285.11K | -1.49%2.82M | 17.81%2.31M | 7.96%1.81M | -37.99%545.16K | -53.19%2.87M | -20.80%1.96M | 37.93%1.68M | 155.61%879.2K | 260.65%6.12M |
| Less:Non operating expense | 192.72%759.91K | -43.65%5.37M | -30.80%1.87M | -74.38%681.43K | -88.45%259.6K | 50.70%9.53M | -52.01%2.7M | -45.43%2.66M | 712.78%2.25M | -62.92%6.32M |
| Total profit | -55.64%133.35M | -69.59%213.39M | -28.48%436.57M | -19.20%417.41M | 24.35%300.6M | -38.23%701.72M | -25.50%610.43M | -10.37%516.63M | -0.10%241.75M | 27.62%1.14B |
| Less:Income tax cost | -43.69%32.22M | -62.19%44.99M | -24.99%77.52M | -19.10%76.91M | 40.32%57.22M | -31.91%118.98M | -32.11%103.34M | -13.15%95.07M | -8.07%40.78M | 52.41%174.73M |
| Net profit | -58.45%101.14M | -71.10%168.41M | -29.19%359.05M | -19.23%340.5M | 21.11%243.39M | -39.38%582.74M | -23.99%507.08M | -9.71%421.56M | 1.68%200.97M | 23.96%961.38M |
| Net profit from continuing operation | -58.45%101.14M | -71.10%168.41M | -29.19%359.05M | -19.23%340.5M | 21.11%243.39M | -39.38%582.74M | -23.99%507.08M | -9.71%421.56M | 1.68%200.97M | 23.96%961.38M |
| Less:Minority Profit | -3,824.43%-757.21K | 40.27%-5.86M | 59.36%-2.97M | 58.60%-1.26M | -95.82%20.33K | -2.89%-9.81M | 28.82%-7.32M | 51.67%-3.05M | 123.13%486.91K | -40.71%-9.54M |
| Net profit of parent company owners | -58.13%101.89M | -70.59%174.27M | -29.62%362.02M | -19.51%341.77M | 21.39%243.37M | -38.97%592.56M | -24.07%514.4M | -10.27%424.61M | 0.37%200.49M | 24.11%970.92M |
| Add:Adjusted items effecting net profit of parent company owners | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0.01 | ---- |
| Earning per share | ||||||||||
| Basic earning per share | -58.82%0.21 | -70.73%0.36 | -29.91%0.75 | -19.32%0.71 | 21.43%0.51 | -39.11%1.23 | -24.11%1.07 | -10.20%0.88 | 0.00%0.42 | 23.93%2.02 |
| Diluted earning per share | -58.82%0.21 | -70.73%0.36 | -29.91%0.75 | -19.32%0.71 | 21.43%0.51 | -38.81%1.23 | -24.11%1.07 | -10.20%0.88 | 0.00%0.42 | 24.07%2.01 |
| Other composite income | 254.25%14.07M | -183.35%-23.89M | -123.83%-1.86M | -150.33%-10.23M | -1,394.26%-9.12M | 93.56%28.67M | 192.74%7.79M | 400.59%20.34M | 86.98%-610.3K | 161.98%14.81M |
| Other composite income of parent company owners | 254.25%14.07M | -183.35%-23.89M | -123.83%-1.86M | -150.33%-10.23M | -1,394.26%-9.12M | 93.56%28.67M | 192.74%7.79M | 400.59%20.34M | 86.98%-610.3K | 161.98%14.81M |
| Total composite income | -50.82%115.2M | -76.36%144.51M | -30.63%357.19M | -25.26%330.27M | 16.92%234.27M | -37.37%611.41M | -21.84%514.87M | -3.97%441.9M | 3.84%200.36M | 29.87%976.19M |
| Total composite income of parent company owners | -50.50%115.96M | -75.79%150.38M | -31.03%360.17M | -25.49%331.53M | 17.20%234.25M | -36.98%621.22M | -21.95%522.19M | -4.61%444.94M | 2.47%199.88M | 29.97%985.73M |
| Total composite income of minority owners | -3,824.43%-757.21K | 40.27%-5.86M | 59.36%-2.97M | 58.60%-1.26M | -95.82%20.33K | -2.89%-9.81M | 28.82%-7.32M | 51.67%-3.05M | 123.13%486.91K | -40.71%-9.54M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
| Auditor | -- | -- | -- | -- | -- | Grant Thornton Certified Public Accountants (Special General Partnership) | -- | -- | -- | Grant Thornton Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.